Intra-Cellular Ther (ITCI)

Feb 21, 2025, 8:00 AM EST - 1 day ago

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results

Jan 21, 2025, 2:35 PM EST - 4 weeks ago

Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?

GSK JNJ LLY NVO PFE

Jan 21, 2025, 6:06 AM EST - 4 weeks ago

Top 4 Health Care Stocks You May Want To Dump In Q1

BBIO BSX ISRG

Jan 16, 2025, 12:10 PM EST - 5 weeks ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of Shareholders

ENFN

Jan 13, 2025, 6:38 PM EST - 5 weeks ago

INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI

JNJ

Jan 13, 2025, 3:13 PM EST - 5 weeks ago

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal

JNJ

Jan 13, 2025, 12:07 PM EST - 5 weeks ago

Drugmakers rush to sign deals on first day of industry conference

ABBV GSK JNJ LLY

Jan 13, 2025, 10:03 AM EST - 5 weeks ago

Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal

JNJ

Jan 13, 2025, 9:25 AM EST - 5 weeks ago

Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B

Jan 13, 2025, 6:38 AM EST - 5 weeks ago

J&J to buy Intra-Cellular Therapies for $14.6 billion

JNJ

Jan 13, 2025, 6:32 AM EST - 5 weeks ago

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

Jan 13, 2025, 5:41 AM EST - 5 weeks ago

This Stock Is Soaring Amid J&J Takeover Report

Jan 12, 2025, 4:35 PM EST - 5 weeks ago

J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports

JNJ

Jan 10, 2025, 6:30 AM EST - 6 weeks ago

Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz

Jan 6, 2025, 8:00 AM EST - 6 weeks ago

Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 11, 2024, 8:00 AM EST - 2 months ago

Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting

Dec 8, 2024, 10:34 PM EST - 2 months ago

Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move

Dec 3, 2024, 7:30 AM EST - 2 months ago

Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy

Nov 19, 2024, 8:00 AM EST - 3 months ago

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

Nov 7, 2024, 8:00 AM EST - 3 months ago

Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress

Nov 5, 2024, 7:14 AM EST - 3 months ago

Intra-Cellular's schizophrenia drug meets main goal in late-stage trial

Oct 30, 2024, 1:34 PM EDT - 4 months ago

Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 7:30 AM EDT - 4 months ago

Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance

Oct 17, 2024, 8:00 AM EDT - 4 months ago

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast

Sep 23, 2024, 8:00 AM EDT - 5 months ago

Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress

Aug 28, 2024, 8:00 AM EDT - 6 months ago

Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences

Aug 8, 2024, 8:00 AM EDT - 7 months ago

Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference

Aug 7, 2024, 3:19 PM EDT - 7 months ago

Intra-Cellular Therapies, Inc. (ITCI) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 7:40 AM EDT - 7 months ago

Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer

Aug 7, 2024, 7:30 AM EDT - 7 months ago

Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance

Jul 24, 2024, 8:00 AM EDT - 7 months ago

Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast

Jun 19, 2024, 2:08 AM EDT - 8 months ago

Intra-Cellular Brightens MDD Outlook With Caplyta Success

Jun 18, 2024, 10:37 AM EDT - 8 months ago

Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study

Jun 18, 2024, 7:30 AM EDT - 8 months ago

Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Jun 10, 2024, 8:00 AM EDT - 9 months ago

Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

May 29, 2024, 8:00 AM EDT - 9 months ago

Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference

May 23, 2024, 8:00 AM EDT - 9 months ago

Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

May 7, 2024, 1:47 PM EDT - 10 months ago

Intra-Cellular Therapies, Inc. (ITCI) Q1 2024 Earnings Call Transcript

May 7, 2024, 7:30 AM EDT - 10 months ago

Intra-Cellular Therapies Reports First Quarter 2024 Financial Results

Apr 30, 2024, 8:00 AM EDT - 10 months ago

Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast

Apr 30, 2024, 4:38 AM EDT - 10 months ago

Intra-Cellular Therapies: Positive MDD Data And Commercial Momentum Make It A Buy

Apr 24, 2024, 4:01 PM EDT - 10 months ago

Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Apr 17, 2024, 8:46 PM EDT - 11 months ago

Intra-Cellular Therapies Prices Public Offering of Common Stock

Apr 16, 2024, 4:06 PM EDT - 11 months ago

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

Apr 16, 2024, 1:17 PM EDT - 11 months ago

Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data

Apr 16, 2024, 7:00 AM EDT - 11 months ago

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Mar 19, 2024, 8:30 AM EDT - 1 year ago

Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes

Mar 11, 2024, 7:11 PM EDT - 1 year ago

Intra-Cellular Therapies Is On Fire